| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
NEW YORK—The Global Preclinical Data Forum (GPDF), a partnership of non-profit research biotech Cohen Veterans Bioscience (CVB) and the European College of Neuropsychopharmacology (ECNP), announced in April the opening of submissions for the 2020 Best Negative Data Prize competition. This prize, which was first launched in 2017, will award €10,000 to the researcher/research group whose publication in neuroscience research best exemplifies data where the results do not confirm the expected outcomes or original hypotheses.
 
The GPDF consists of members from the academic, non-profit, government, publishing and industry sectors and aims to encourage global collaboration to address the challenge of ensuring that preclinical research is reproducible, robust and translatable to support disease research utility for clinical research and development. One of the group’s major focuses is to provide quality resources and promote the publication of “negative” data—results of studies where researchers are not able to confirm or replicate previous findings—which are often not submitted for publication.
 
“Science is a progressive build and, at its essence, self-correcting, but we know it can be much more informative if both positive and negative data are published for all scientists to see,” said Dr. Magali Haas, CEO of CVB and co-chair of the U.S. branch of the GPDF. “Unfortunately, the scientific community is not motivated to publish ‘negative’ results, as they are not seen as advantageous for the scientist, organization and journal. This, unfortunately, is a disservice to the scientific community, as not sharing negative unpublished data is a waste of human capital and valuable resources and can lead to the duplication of efforts by others in the field. In fact, the estimated costs of this ‘lost’ science in the U.S. alone is $28 billion dollars annually.”
 
The closing date for submissions was April 21, just a couple weeks after the announcement that they had opened, but if you are interested in the results (to be announced Sept. 12) or want to submit something for next year, visit http://www.preclinicaldataforum.org for more information.

Related Topics

Published In

Volume 16 - Issue 6 | June 2020

June 2020

June 2020 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue